	US 12,077,596 B2
	Multispecific antibodies against CD40 and CD137
Isil Altintas, Utrecht (NL); David Satijn, Utrecht (NL); Rik Rademaker, Utrecht (NL); Paul Parren, Odijk (NL); Friederike Gieseke, Mainz (DE); and Ugur Sahin, Mainz (DE)
Assigned to GENMAB A/S, Valby (DK); and BioNTech SE, Mainz (DE)
Filed by GENMAB A/S, Copenhagen V (DK); and BioNTech SE, Mainz (DE)
Filed on Jun. 28, 2021, as Appl. No. 17/360,438.
Application 17/360,438 is a division of application No. 16/316,534, granted, now 11,091,557, previously published as PCT/EP2017/067924, filed on Jul. 14, 2017.
Claims priority of application No. PCT/EP2016/066840 (WO), filed on Jul. 14, 2016.
Prior Publication US 2022/0033510 A1, Feb. 3, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); G01N 33/569 (2006.01)

CPC C07K 16/2878 (2013.01) [A61K 39/3955 (2013.01); G01N 33/56972 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)]

20 Claims

1. A method of treating cancer in a subject, comprising administering to the subject a multispecific antibody, wherein the multispecific antibody comprises:

(I) a first binding arm comprising a first antigen-binding region binding to human CD40, wherein said first antigen-binding region comprises heavy (VH) and light (VL) chain variable region CDR1, CDR2, and CDR3, the heavy chain variable region CDR1, CDR2, and CDR3 having the amino acid sequences set forth in SEQ ID NOs:1, 2 and 3, respectively, and light chain variable region CDR1, CDR2 and CDR3 having the amino acid sequences set forth in SEQ ID NO:4, YTS and SEQ ID NO: 5, respectively; and

(II) a second binding arm comprising a second antigen-binding region binding to human CD137 comprising a variable chain heavy (VH) region and a variable chain light (VL) region.